of your
patients’ kidney health in your practice.
Easy to start.
A non-fasting, simple blood test is available to risk stratify your patient base.
Easy to find out who
needs more vs. less attention.
The kidneyintelX.dkd test provides a highly reliable, meaningful risk result and the confidence to assess whether your patient is at low, moderate, or high risk for progression.
Easy to know what to do next.
Each test report, with an individual’s risk result, is simple to understand and can help you determine which patients will benefit most from recommended therapies outlined by the ADA, AAFP, and KDIGO guidelines, and/or consultation with a specialist.
Experienced Medical Affairs Team on call.
Renalytix, the founder of kidneyintelX.dkd, understands the importance of clinical support and information exchange. That’s why we are committed to providing a Medical Affairs Team who can educate regarding our proprietary methodology, evidential studies, test protocol, patient results, and pharmacy management.
Small changes can yield big results.
Until about a decade ago, available drugs for chronic kidney disease were insufficient, and significant disease progression still occurred in clinical trials and in clinical practice.
There are now multiple, effective therapeutics available that can prevent kidney failure and cardiovascular complications, which is the major cause of death in these patients.
Small changes to a treatment plan can yield meaningful results in chronic disease management. Together, the insights from kidneyintelX.dkd testing, care management, and available pharmacy resources, can help clinicians match a patient’s level of risk with the therapies employed.
Are the therapies you’re using now… optimized?